IFNA1 and cutaneous melanoma: More recently, a randomized phase III trial including patients with resected cutaneous melanoma stage IIA-IIIB showed that pegylated IFN-α did not improve the outcome over IFN Notably, a higher percentage of patients under pegylated IFN-α discontinued treatment due to toxicity (52).